AC Immune SA (NASDAQ: ACIU) reported shares going upward early Monday, after reporting its financial results for the quarter ended September 30, 2021 and provided a corporate update.
This morning’s news release said total cash position does not include total gross proceeds of $30 million U.S. received in October 2021 from (i) $5 million U.S. as part of the Affiris asset acquisition and (ii) $25 million U.S. as part of a private placement with select group of Affiris investors.
The Company recognized CHF 0.3 million in grant income for R&D activities performed under our Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Target ALS grants, a decrease of CHF 0.2 million compared to the prior period. The Company reported a net loss after taxes of CHF 15.9 million for the three months ended September 30, 2021, compared with a net loss of CHF 19.0 million for the comparable period in 2020.
CEO Andrea Pfeifer, CEO of AC Immune SA, commented: "AC Immune concluded an exceptional third quarter, highlighted by the acquisition of a clinical α-syn vaccine candidate in Parkinson’s disease and topline Phase 2 Lauriet data showing that semorinemab was the first Tau antibody candidate to significantly slow cognitive decline in mild-to-moderate Alzheimer’s disease patients.
"Our partner Genentech, a member of the Roche Group, will present the topline Lauriet data, later this week at the CTAD 2021 conference, where we will present new clinical data on our p-Tau and Abeta vaccine candidates, ACI-35 and ACI-24, respectively."
AC Immune is a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases. Its shares began Monday up four cents to $7.37.
